ASTRAZENECA AB
🇪🇸Spain
Clinical Trials
3.0k
Active:2725
Completed:65
Trial Phases
5 Phases
Phase 1:1939
Phase 2:49
Phase 3:197
+2 more phases
Drug Approvals
136
NMPA:100
EMA:36
Drug Approvals
Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol
- Product Name
- 格隆溴铵福莫特罗吸入气雾剂
- Approval Number
- 国药准字HJ20200012
- Approval Date
- Dec 13, 2024
NMPA
Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol
- Product Name
- 布地格福吸入气雾剂
- Approval Number
- 国药准字HJ20190063
- Approval Date
- Sep 2, 2024
NMPA
Sodium Zirconium Cyclosilicate Powder
- Product Name
- 利倍卓
- Approval Number
- 国药准字HJ20190072
- Approval Date
- May 31, 2024
NMPA
Sodium Zirconium Cyclosilicate Powder
- Product Name
- 利倍卓
- Approval Number
- 国药准字HJ20190073
- Approval Date
- May 31, 2024
NMPA
Budesonide and Formoterol Fumarate Powder for Inhalation（II）
- Product Name
- 信必可都保
- Approval Number
- 国药准字HJ20140457
- Approval Date
- Feb 23, 2024
NMPA
Budesonide and Formoterol Fumarate Powder for Inhalation（II）
- Product Name
- 信必可都保
- Approval Number
- 国药准字HJ20140458
- Approval Date
- Feb 23, 2024
NMPA
Budesonide and Formoterol Fumarate Powder for Inhalation（I）
- Product Name
- 信必可都保
- Approval Number
- 国药准字HJ20140459
- Approval Date
- Feb 23, 2024
NMPA
Metoprolol Succinate Sustained-release Tablets
- Product Name
- 倍他乐克
- Approval Number
- 国药准字HJ20140777
- Approval Date
- Dec 20, 2023
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
Clinical Trials
Distribution across different clinical trial phases (2243 trials with phase data)• Click on a phase to view related trials
Phase 1
1939 (86.4%)Phase 3
197 (8.8%)Phase 2
49 (2.2%)Not Applicable
41 (1.8%)phase_1_2
7 (0.3%)Phase 4
7 (0.3%)phase_2_3
2 (0.1%)1 (0.0%)
A Phase III, Randomized, Double blind, Placebo controlled, Multi centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum based, Concurrent Chemoradiation Therapy (eVOLVE Cervical)
Phase 3
Not yet recruiting
- Conditions
- D069 Cervix, unspecifiedCervix, unspecifiedD069
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele
Phase 2
Recruiting
- Conditions
- K75 NULL
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- AstraZeneca AB
- Target Recruit Count
- 1
- Registration Number
- PER-016-23
News
No news found